TRACON Pharmaceuticals, Inc.
TCON · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $3 | $0 |
| % Growth | -45% | -96.7% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $3 | -$0 |
| % Margin | 100% | 96% | 99.9% | – |
| R&D Expenses | $1 | $2 | $1 | $2 |
| G&A Expenses | $2 | $1 | $1 | $1 |
| SG&A Expenses | $2 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$0 | $0 |
| Operating Expenses | $3 | $3 | $3 | $4 |
| Operating Income | -$3 | -$3 | $0 | -$2 |
| % Margin | -5,294.5% | -3,212% | 13.4% | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $12 |
| Pre-Tax Income | -$3 | -$3 | $0 | $11 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3 | -$3 | $0 | $11 |
| % Margin | -5,161.8% | -3,168% | 14.4% | – |
| EPS | -0.94 | -1.33 | 0.22 | 5.85 |
| % Growth | 29.3% | -704.5% | -96.2% | – |
| EPS Diluted | -0.94 | -1.33 | 0.18 | 5.8 |
| Weighted Avg Shares Out | 3 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 3 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$3 | $0 | $11 |
| % Margin | -5,287.3% | -3,208% | 13.3% | – |